Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

Gain valuable insights into novel therapies, ongoing clinical trials, and future innovations shaping the treatment of ...

8 Humoral and cellular responses to the AAV capsid and factor IX were ... Ten participants with hepatitis C, 7 with hepatitis B, and 2 with human immunodeficiency virus (HIV) infection were ...

Assembly Biosciences, Inc.’s ASMB share price has surged by 5.74%, which has investors questioning if this is right time to ...

HBV=hepatitis B virus. HBVDR=HBV drug resistance ... 78 new classes of antiviral agents are in trials (eg, small interfering RNA, capsid assembly inhibitors, and immunotherapies). 79 In most cases, ...

including amendment to accelerate clinical development of Assembly Bio’s novel small molecule hepatitis D virus candidate ABI-6250— SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE ...

‘We picked those two sites in part because they have a very high prevalence of chronic hepatitis B, but also because the two most prominent ... the company revealed preclinical data on an ...

There's a vaccine for hepatitis B that, according to the CDC, can help to prevent millions of deaths worldwide.